secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001104659-26-032950
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee reports positive Phase 2 52-week zumilokibart data; durable maintenance with 3- and 6-month dosing
--------------------------------------------------------------------------------

- EASI-75 maintained in 75% (3-month) and 85% (6-month) of Week 16 responders; vIGA 0/1 maintained in 86% and 78%.
- Deepening of response across all endpoints over 52 weeks in the full zumilokibart-treated population.
- Safety profile consistent with class; common TEAEs: noninfective conjunctivitis (13.4%), URTI (12.6%), nasopharyngitis (9.2%).
- Part B 16-week induction data expected Q2 2026; Phase 3 initiation in 2H 2026; potential commercial launch in 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465926032950/0001104659-26-032950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465926032950/tm269553d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-032950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer